At another interview stop along Pharma’s Almanac’s Road to 2021 trip, Chainbridge Pharma’s Managing Director and Founder Kristof Szent-Ivanyi and Nigel discuss the pandemic’s impact on sustainability.
Kristof retired from GSK after 22 years of successful service in broad range of sales, PR and supply chain leadership roles. He established and headed up the global GSK CDMO Business and developed it to a £300 million business. Kristof also led one of the newest antibiotic CDMO projects — Avicaz — from its inception and up to market for Allergan and AstraZeneca. His established consultancy company, ChainbridgePharma helps the industry to develop their portfolio further on the NCE and the generic front, providing access to ANDAs and other materials.
.svg)
